Immunovant, Inc. (IMVT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.28: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 21%; Below-average business quality.
Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor targeting IgG-mediated autoimmune diseases, with potentially registrational trials underway in Graves' disease, myasthenia gravis, CIDP, D2T RA, and a proof-of-concept trial in cutaneous... Read more
Sell if holding. Engine safety override at $35.28: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 21%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
Recent Developments — Immunovant, Inc.
Latest news
- Immunovant Stock Surges Despite Disappointing Earnings Miss — benzinga May 20, 2026 positive
- 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga May 20, 2026 neutral
- Crude Oil Down 5%; Lowe's Posts Upbeat Earnings — benzinga May 20, 2026 neutral
- TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wed — benzinga May 20, 2026 positive
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session — benzinga May 20, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.28: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 21%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $32.47. Score 4.6/10, moderate confidence.
Take-profit target: $36.26 (+3.9% upside). Prior stop was $32.47. Stop-loss: $32.47.
Quality below floor (1.2 < 4.0).
Immunovant, Inc. trades at a P/E of N/A (forward -10.2). TrendMatrix value score: 5.0/10. Verdict: Sell.
24 analysts cover IMVT with a consensus score of 4.1/5. Average price target: $40.
What does Immunovant, Inc. do?Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor targeting IgG-mediated...
Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor targeting IgG-mediated autoimmune diseases, with potentially registrational trials underway in Graves' disease, myasthenia gravis, CIDP, D2T RA, and a proof-of-concept trial in cutaneous lupus. The company has no approved products and funds operations primarily through equity. First top-line data from registrational studies is not expected until 2027.